Enhertu Gets EU CHMP Backing for Early Breast Cancer — 53% Recurrence Risk Cut
AZN is trading near its 52-week low of $146.1 (14% above the low).
Summary
CHMP recommended EU approval of Enhertu as adjuvant treatment for HER2-positive early breast cancer with residual disease, based on a 53% reduction in recurrence or death risk versus T-DM1.
Key Events · Product Development and Regulatory · AZN
-
CHMP Positive Opinion for Enhertu
EU regulators recommended approval of Enhertu as adjuvant monotherapy for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant treatment.
-
DESTINY-Breast05 Efficacy Data
Enhertu cut the risk of invasive disease recurrence or death by 53% versus T-DM1 (HR 0.47; 95% CI 0.34-0.66, p<0.0001).
-
Three-Year Disease-Free Survival
92.4% of Enhertu patients were alive and free of invasive disease at three years, versus 83.7% for T-DM1.
-
Market Expansion into Early-Stage Setting
Approval would move Enhertu into the curative-intent adjuvant setting, where about one in three HER2-positive early breast cancer patients is high-risk.
Analysis · AZN · Life Sciences
A key EU regulatory hurdle has been cleared for Enhertu, with the CHMP recommending approval as adjuvant therapy for HER2-positive early breast cancer patients with residual disease after neoadjuvant treatment. The recommendation is underpinned by DESTINY-Breast05 data showing a 53% reduction in invasive disease recurrence or death versus T-DM1, with 92.4% of Enhertu patients alive and disease-free at three years versus 83.7% for T-DM1. This expands Enhertu's addressable market from metastatic settings into the larger curative-intent early-stage population, where roughly one in three HER2-positive patients is considered high-risk. Final European Commission approval typically follows a positive CHMP opinion within a few months.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $167.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $257.6B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.